Monte Rosa Therapeutics (GLUE) Change in Accured Expenses (2020 - 2026)

Monte Rosa Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$3.7 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 42.44% year-over-year to -$3.7 million in Q1 2026; TTM through Mar 2026 was $6.7 million, a 23.46% increase from a year earlier, with the FY2025 full-year figure at $7.9 million, up 87.67% from the prior year.
• Change in Accured Expenses declined to -$3.7 million in Q1 2026 per GLUE's latest filing, from $8.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $8.7 million in Q4 2025 and bottomed at -$3.9 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $1.4 million (2022), against an average of $759529.4.
• Biggest YoY gain for Change in Accured Expenses was 1590.65% in 2022; the steepest drop was 382.25% in 2022.
• Year by year, Change in Accured Expenses stood at $2.1 million in 2022, then slumped by 37.79% to $1.3 million in 2023, then jumped by 186.81% to $3.7 million in 2024, then surged by 136.27% to $8.7 million in 2025, then sank by 142.5% to -$3.7 million in 2026.
• Per Business Quant, the three latest GLUE Change in Accured Expenses figures stand at -$3.7 million (Q1 2026), $8.7 million (Q4 2025), and $4.2 million (Q3 2025).